Published in Cancer Weekly, September 4th, 2001
The EGFR protein tyrosine kinase inhibitor (PKI) PKI 166, when given three times a week in combination with intraperitoneal injections of gemcitabine to mice bearing pancreatic tumors, inhibited tumor proliferation and angiogenesis and increased tumor cell apoptosis, researchers at the University of Texas M.D. Anderson Cancer Center in Houston reported. Eventually, the novel therapy could prove useful for treating humans with pancreatic carcinoma, a leading cause of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.